Key Highlights•
448-patient Phase 2 clinical trial in osteoarthritis expected to commence in 2H 2019
Costs of trial substantially funded by NHMRC; no cash contribution from Cynata
Cynata to supply Cymerus MSCs to facilitate the trial
This trial will be one of the largest MSC trials ever run, representing a breakthrough achievement for Cynata and showcasing its capacity to produce MSCs at scale
•Cynata retains full commercial rights to the use of Cymerus MSCs in osteoarthritis, representing a market opportunity forecast to be worth US$11.6 billion globally by 2025
•Osteoarthritis becomes the third Phase 2 indication for Cynata, highlighting demand for the company’s Cymerus MSCs in multiple indications
•Trial will take place in Sydney and Tasmania, and will be managed by a world-class clinical team led by Professor David Hunter of the University of Sydney
Key Highlights•448-patient Phase 2 clinical trial in...
-
- There are more pages in this discussion • 193 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
0.030(12.5%) |
Mkt cap ! $48.50M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 29.5¢ | 26.0¢ | $113.1K | 420.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4999 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 3935 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |